EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts

Marcus M Ilg, Alice R Lapthorn, Sophie L Harding, Tariq Minhas, Gouri Koduri, Stephen A Bustin, Selim Cellek

Frontiers in Pharmacology · 13.02.2025 · 16

DOI: 10.3389/fphar.2025.1526495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.02.2025. Verfasst von Marcus M Ilg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Fibrosis Research Group, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford, United Kingdom. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biochemical Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In cancer metastasis, tumor cells condition distant tissues to create a supportive environment, or metastatic niche, by driving the activation of cancer-associated fibroblasts (CAFs). These CAFs remodel the extracellular matrix, creating a microenvironment that supports tumor growth and compromises immune cell function, enabling cancer cells to evade immune detection. Consequently, targeting the activation of CAFs has been proposed as a therapeutic strategy to hinder metastatic spread. Our objective was to develop the first in vitro phenotypic screening assay capable of assessing this activation process.

Methods

Human primary lung fibroblasts were co-cultured with highly invasive breast cancer cells (MDA-MB-231) to identify changes in the expression of selected genes using RT-qPCR. An In-Cell ELISA (ICE)-based assay using human lung fibroblasts, MDA-MB-231 cells and human monocytes (THP-1 cells) was developed to measure the activation of CAFs. Another ELISA assay was used to measure released osteopontin.

Results

When lung fibroblast were co-cultured with MDA-MB-231 cells, among the 10 selected genes, the genes for osteopontin (SPP1), insulin like growth factor 1 (IGF1), periostin (POSTN) and α-smooth muscle actin (α-SMA, ACTA2) elicited the greatest fold change (55-, 37-, 8- and 5-fold respectively). Since osteopontin, IGF-1 and periostin are secreted proteins and α-SMA is an intracellular cytoskeleton protein, α-SMA was chosen to be the readout biomarker for the ICE assay. When fibroblasts were co-cultured with MDA-MB-231 cells and monocytes in the 96 well ICE assay, α-SMA expression was increased 2.3-fold yielding a robust Z′ of 0.56. A secondary, low throughput assay was developed by measuring the release of osteopontin which showed a 6-fold increase when fibroblasts were co-cultured with MDA-MB-231 cells and monocytes.

Discussion

This phenotypic assay is the first to measure the activation of CAFs in a 96-well format, making it suitable for medium-to high-throughput screening of potential therapeutic compounds. By focusing on observable cellular phenotypic changes rather than targeting specific molecular pathways, this assay allows for a broader and unbiased identification of compounds capable of modulating CAF activation.

Schlagwörter

Stichwörter der Autor:innen

assaycancerdrug discoveryfibroblastmetastasismyofibroblastphenotypicscreening

Autor:innen und Institutionen

  • Fibrosis Research Group, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford, United Kingdom.
  • The Essex Cardiothoracic Centre, Basildon University Hospital, Basildon, United Kingdom.
  • Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom.

Förderung

  • Biochemical Society

Zitieren

APA

Ilg, M. M., Lapthorn, A. R., Harding, S. L., Minhas, T., Koduri, G., Bustin, S. A., & Cellek, S. (2025). Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1526495

Vancouver

Ilg MM, Lapthorn AR, Harding SL, Minhas T, Koduri G, Bustin SA, et al. Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1526495

BibTeX
@article{Ilg2025,
  author = {Ilg, Marcus M and Lapthorn, Alice R and Harding, Sophie L and Minhas, Tariq and Koduri, Gouri and Bustin, Stephen A and Cellek, Selim},
  title = {Development of a phenotypic screening assay to measure activation of cancer-associated fibroblasts},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1526495}
}
Kostenlos starten →